The findings indicated that individuals with elevated NCAPH expression levels, particularly those diagnosed with WHO grade III glioma, exhibited unfavorable prognoses in both primary and recurrent cases (Figure 5R-W). The gene discussed is NCAPH; the disease is central nervous system cancer.